Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Beauty Farm Medical & Health Industry, Inc. ( (HK:2373) ) has issued an update.
Beauty Farm Medical and Health Industry Inc. has deployed idle funds into principal-guaranteed wealth management products issued by SPD Bank via its subsidiaries Beijing Palaispa and Shanghai Beauty Farm Medical and Health. The subscriptions, made between November 21, 2025 and February 13, 2026, total RMB240 million and all products remain outstanding.
Individually, each subscription falls below the disclosure thresholds under Hong Kong listing rules, but the transactions are aggregated because they involve the same counterparty, are similar in nature, and occur within a 12‑month period. On an aggregated basis, one or more percentage ratios exceed 5% but remain below 25%, making the combined wealth management product investments a discloseable transaction subject to notification and announcement requirements, signaling a notable treasury management move for stakeholders to monitor.
The most recent analyst rating on (HK:2373) stock is a Hold with a HK$30.00 price target. To see the full list of analyst forecasts on Beauty Farm Medical & Health Industry, Inc. stock, see the HK:2373 Stock Forecast page.
More about Beauty Farm Medical & Health Industry, Inc.
Beauty Farm Medical and Health Industry Inc., incorporated in the Cayman Islands and listed in Hong Kong, operates in the medical and health services sector, with operations in mainland China through subsidiaries including Beijing Palaispa and Shanghai Beauty Farm Medical and Health. The group focuses on consumer-facing medical, wellness and beauty services, positioning itself in the broader healthcare and aesthetics market.
Average Trading Volume: 462,418
Technical Sentiment Signal: Hold
Current Market Cap: HK$6.49B
Learn more about 2373 stock on TipRanks’ Stock Analysis page.

